![]() ![]() In severe renal insufficiency, the initial dose is 5-10 mg / day.ĭigestive system: constipation, diarrhea, loss of appetite, flatulence, nausea, abdominal pain, pancreatitis, increased ALT, AST, GGT, ALP.ĬNS and peripheral nervous system: headache, dizziness, muscle cramps, paresthesia, peripheral neuropathy.Ĭardiovascular system: possible transient hypotension. The maximum dose is 40 mg / day.įor patients receiving immunosuppressive drugs, the recommended starting dose is 5 mg the maximum dose is 5 mg / day. Eurocor is taken 1 time / day in the evening. If necessary the dose is increased every 4 weeks. ![]() The dosing regimen of Eurocor is individual. Primary hypercholesterolemia with the ineffectiveness of diets, combined hypercholesterolemia and hypertriglyceridemia. The concentration of the active metabolite of Eurocor in human systemic circulation is less than 5%.Įxcreted in unchanged form and as metabolites, mainly in the bile - 60-85%, 10-15% - in the form of inactive metabolites are excreted by the kidneys. Taking Eurocor just before eating with low fat does not affect its the pharmacokinetic parameters.ĭuring a "first pass" through the liver Eurocor biotransformed to form active beta-metabolites. There is evidence that Eurocor improves endothelial function within 30 days of therapy.Įurocor therapy was accompanied by a decrease in the incidence of cardiovascular disorders, regardless of baseline LDL-C.Īfter oral administration Eurocor is well absorbed from the gastrointestinal tract (average 85%). In addition to the hypolipidemic actions Eurocor has beneficial effects in endothelial dysfunction, on the vascular wall, the state of atheroma, improves blood rheology, have antioxidant, antiproliferative properties. Statins do not affect the activity of lipoprotein and hepatic lipase, have no significant effect on the synthesis and catabolism of free fatty acids, thats why their effect on TG levels again and indirectly through their main effects on reducing LDL-C.Īccording to the controlled studies of Eurocor increases HDL-C to 14%. Reducing cholesterol is dose-dependent and is not linear but exponential. Lipid-lowering effect of statins is associated with lower levels of total cholesterol by LDL-C. This medication is a prodrug because it has in its structure the closed lactone ring which is hydrolyzed after intake. Eurocor is a hypolipidemic agent from a group of statins, an inhibitor of HMG-CoA reductase. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |